The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Goryunov A.V.

Mental Health Research Center

Using Lurasidone in the treatment of mental illness in childhood

Authors:

Goryunov A.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(11‑2): 77‑85

DOI: 10.17116/jnevro202112111277

Read: 7922 times

Contact the author
Table of contents

USING LURASIDONE IN THE TREATMENT OF MENTAL ILLNESS IN CHILDHOOD
USING LURASIDONE IN THE TREATMENT OF MENTAL ILLNESS IN CHILDHOOD

To cite this article:

Goryunov AV. Using Lurasidone in the treatment of mental illness in childhood. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(11‑2):77‑85. (In Russ.)
https://doi.org/10.17116/jnevro202112111277

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Aripiprazole in the treatment of psychiatric diso­rders in childhood. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):38-47
Age transformation of leading clinical diagnoses in adolescents and young people with non-suicidal self-harm. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):48-56
Cognitive dysfunction in children with nervous system diseases: modern approaches to diagnosis and treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):69-79
Modern concepts of sleep disturbances asso­ciated with mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):7-12
Asso­ciation of cortisol levels with psychopathological features of depression and therapeutic response in female patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):45-54
Factors supporting chro­nic inflammation in mental illness. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):7-15
Nasal glial hete­rotopia in children: a review of the lite­rature and a series of our own obse­rvations. Russian Bulletin of Otorhinolaryngology. 2025;(4):58-58
Features of stru­cture of the crista galli in children with dermoid cyst of the exte­rnal nose and deviation of the nasal septum. Russian Rhinology. 2025;(3):209-216
Rhinogenic orbi­tal complications in children of the first year of life. Russian Bulletin of Otorhinolaryngology. 2025;(5):41-47
Constitutional and morphological bases of suicidal beha­vior in patients with schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):52-56
Abstract:

Lurasidone is one of the newest antipsychotics approved for use in childhood. The review presents generalized data on the pharmacological profile of Lurasidone, preclinical and clinical studies of the drug with an analysis of the parameters of pharmacodynamics, pharmacokinetics, clinical efficacy, tolerability and safety of therapy for schizophrenia and bipolar disorder in children. It also provides data on the off-lable use of Lurasidone in childhood for autism spectrum disorders, Tourette’s syndrome, hypomania in the structure of bipolar affective disorder. The data on the efficacy of Lurasidone in a wide range of psychopathological disorders, including positive, negative, affective and cognitive domains, as well as a favorable tolerability profile of the drug, including long-term therapy, are presented.

Keywords:

childhood
schizophrenia
bipolar disorder
antipsychotic therapy
lurasidone

Authors:

Goryunov A.V.

Mental Health Research Center

Received:

08.12.2021

Accepted:

08.12.2021

Close metadata

References:

  1. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, Burstein R, Murray CJ, Vos T. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1575-1586. https://doi.org/10.1016/S0140-6736(13)61611-6
  2. Pagsberg AK, Tarp S, Glintborg D, Stenstrøm AD, Fink-Jensen A, Correll CU, Christensen R. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis. J Am Acad Child Adolesc Psychiatry. 2017;56(3):191-202.  https://doi.org/10.1016/j.jaac.2016.12.013
  3. Sivolap IuP. Typical and atypical antipsychotics: how significant are the differences? Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2018;118(11):125-129. (In Russ.). https://doi.org/10.17116/jnevro2018118111125
  4. Portnova AA, Sivolap YuP. Challenges of the use of antipsychotics in children and adolescents. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2019;119(11):123-127. (In Russ.). https://doi.org/10.17116/jnevro2019119111123
  5. Mosolov SN, Tsukarzi EE, Alfimov PV. Algorithms for biological therapy of schizophrenia. Modern therapy of mental disorders. 2014;1:27-36. (In Russ.).
  6. Alfimov PV, Ryvkin PV, Ladyzhenskii MYa, Mosolov SN. Metabolic syndrome in patients with schizophrenia (literature review). Modern therapy of mental disorders. 2014;3:8-14. (In Russ.).
  7. Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry. 2011;68(6):609-616.  https://doi.org/10.1001/archgenpsychiatry.2011.2
  8. Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH, Pikalov A, Potkin SG: Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013;145:101-109.  https://doi.org/10.1016/j.schres.2013.01.009
  9. Nasrallah H, Silva R, Phillips D, Cucchiaro J, Hsu J, Xu J, Loebel A: Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47:670-677.  https://doi.org/10.1016/j.jpsychires.2013.01.020
  10. Ogasa M, Kimura T, Nakamura M, Guarino J: Lurasidone in the treatment of schizophrenia: A 6-week, placebo-controlled study. Psychopharmacology (Berl). 2013;225:519-530.  https://doi.org/10.1007/s00213-012-2838-2
  11. Loebel A, Citrome L: Lurasidone: A novel antipsychotic agent for the treatment of schizophrenia and bipolar depression. BJPsych Bull. 2015;39:237-241.  https://doi.org/10.1192/pb.bp.114.048793
  12. Jaeschke R, Sowa-Kućma M, Pańczyszyn-Trzewik P, Misztak P, Styczeń K, Datka W. Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile. J Pharmacol Rep. 2016;68(4):748-755.  https://doi.org/10.1016/j.pharep.2016.04.002
  13. Iyo M, Ishigooka J, Nakamura M, Sakaguchi R, Okamoto K, Mao Y, Tsai J, Fitzgerald A, Takai K, Higuchi T Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study. J Neuropsychiatric Disease and Treatment. 2021;17:2683-2695. Neuropsychiatr Dis Treat. 2021;17:2683-2695. https://doi.org/10.2147/NDT.S320021
  14. Oleichik IV, Baranov PA, Shishkovskaya TI, Sizov SV. Efficacy and safety of the atypical third-generation antipsychotic lurasidone in the treatment of depressive conditions developing in the framework of schizophrenia. Modern therapy of mental disorders. 2021;2:28-35. (In Russ.). https://doi.org/10.21265/PSYPH.2021.57.2.004
  15. Nasrallah HA, Cucchiaro JB, Mao Y, Pikalov AA, Loebel AD. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 65week, placebo controlled studies. CNS Spectrums. 2015;2(20):140-147.  https://doi.org/10.1017/S1092852914000285
  16. Bekker RA, Bykov YuV. Efficacy and safety of the third generation antipsychotic lurasidone (Latuda) in schizophrenia and bipolar depression. Psychiatry and psychopharmacotherapy. 2019;4(21):20-33. (In Russ.).
  17. Rettenbacher M, Hofer A, Ebenbichler C, et al. Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment. J Clin Psychopharmacol. 2010;30(6):711-715.  https://doi.org/10.1097/jcp.0b013e3181faf0e3
  18. Stahl SM. Prescriber’s Guide. Children and Adolescents. UK. Publisher: Cambridge University; 2019.
  19. Amy FT. Arnsten, The Neurobiology of Thought: The Groundbreaking Discoveries of Patricia Goldman-Rakic 1937—2003, Cerebral Cortex. 2013;23:10:2269-2281. https://doi.org/10.1093/cercor/bht195
  20. Shahid, M et al. (2008). Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. Journal of Psychopharmacology, 23(1), 65–73 
  21. Mauri MC, Paletta S, Maffini M et al. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J. 2014;13:1163-1191. PMID: 26417330.
  22. Okada M, Matsumoto R, Yamamoto Y, Fukuyama K. Effects of Subchronic Administrations of Vortioxetine, Lurasidone, and Escitalopram on Thalamocortical Glutamatergic Transmission Associated with Serotonin 5-HT7 Receptor. Int J Mol Sci. 2021;22(3):1351. https://doi.org/10.3390/ijms22031351
  23. Huang M, Kwon S, Rajagopal L, He W, Meltzer H.Y. 5-HT 1A parital agonism and 5-HT 7 antagonism restore episodic memory in subchronic phencyclidine-treated mice: role of brain glutamate, dopamine, acetylcholine and GABA. Psychopharmacology (Berl). 2018;10:235(10):2795-2808. https://doi.org/10.1007/s00213-018-4972-y
  24. Instructions for medical use of the drug Lurasidone. (In Russ.). https://www.lsgeotar.ru/lurazidon.html
  25. Thompson J, et al. Prefrontal dopamine D1 receptors and working memory in schizotypal personality disorder: A PET study with [(1)(1)C] NNC112. Psychopharmacology. 2014;231:4231-4240. https://doi.org/10.1007/s00213-014-3566-6
  26. Makushkin EV, Simashkova NV, Perezhogin LO, Goryunov AV. Schizophrenia in childhood and adolescence. Russian Psychiatric Journal. 2016;6:62-81. (In Russ.).
  27. Sadock BJ, Sadock VA., Ruiz P. Kaplan and Sadock’s Comprehensive textbook of psychiatry. 2017. Ed.10, Wolters Kluwer Health, p. 4998.
  28. Zvereva NV, Strogova SE, Koval-Zaytsev AA, Simashkova NV, Khromov AI, Vlasenova IN. On the problem of psychological (psychometric) diagnosis of intelligence in children with developmental disorders]. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2015;115(5-2):21-27. (In Russ.). https://doi.org/10.17116/jnevro20151155221-27
  29. Ohi K, Sumiyoshi C, Fujino H, Yasuda Y, Yamamori H, Fujimoto M, Shiino T, Sumiyoshi T, Hashimoto R. Genetic Overlap between General Cognitive Function and Schizophrenia: A Review of Cognitive GWASs. Int J Mol Sci. 2018;19(12):3822. https://doi.org/10.3390/ijms19123822
  30. Remschmidt H, Theisen F. Early-onset schizophrenia. Neuropsychobiology. 2012;66(1):63-69.  https://doi.org/10.1159/000338548
  31. Smulevich AB, Romanov DV, Voronova EI, Mukhorina AK, Chitlova VV, Sorokina OYu. Evolution of the schizophrenic deficit concept. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2017;117(9):4-14. (In Russ.). https://doi.org/10.17116/jnevro2017117914-14
  32. Kozlova IA. The current state of the doctrine of childhood schizophrenia. Journal of Psychiatry. 2008;3(33):7-12. (In Russ.). https://ncpz.ru/stat/179
  33. Smulevich AB. Negative Disorders in Schizophrenia. M.: MEDpress Inform Publishers; 2021. (In Russ.).
  34. Kozlova IA, Goryunov AV, Koval-Zaitsev AA. Experience of using cerebrolysin in complex therapy of childhood schizophrenia without exacerbation. Journal «Psychiatry». 2009;2:24-33. (In Russ.).
  35. Burelomova IV, Masikhina SN, Goryunov AV, Grebchenko YuF. Experience of using the drug rispolept in childhood schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2001;101(7):56-63. (In Russ.).
  36. Kennedy E, Kumar A, Datta S. Antipsychotic medication for childhood-onset schizophrenia. Cochrane Database Syst Rev. 2007;2007(3):CD004027. https://doi.org/10.1002/14651858.CD004027.pub2
  37. Findling RL, Goldman R, Chiu Y, Silva R, Jin F, Pikalov A, Loebel A. Pharmacokinetics and Tolerability of Lurasidone in Children and Adolescents With Psychiatric Disorders. Clinical Therapeutics. 2015;37(12):2788-2797. https://doi.org/10.1016/j.clinthera.2015.11.001
  38. Goldman R, Loebel A, Cucchiaro J, Deng L, Findling R. Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study. J Child Adolescent Psychopharmacol. 2017;27(6):516-525.  https://doi.org/10.1089/cap.2016.0189
  39. Correll C, Findling R, Tocco M, Pikalov A, Deng L, Goldman R. Safety and effectiveness of lurasidone in adolescents with schizophrenia: Results of a 2-year, open-label extension study. CNS Spectrums. 2020.1-11.  https://doi.org/10.1017/S1092852920001893
  40. Arango C, Ng-Mak D, Finn E, et al. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis. Eur Child Adolesc Psychiatry. 2020;29:1195-1205. https://doi.org/10.1007/s00787-019-01425-2
  41. Channing J, Mitchell M, Cortese S.Lurasidone in Children and Adolescents: Systematic Review and Case Report. J Child Adolesc Psychopharmacol. 2018;28(7):428-436.  https://doi.org/10.1089/cap.2018.0046
  42. Goryunov AV. Depression in schizotypal disorder in childhood and adolescence. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2021;121(5-2):11-17. (In Russ.). https://doi.org/10.17116/jnevro202112105212
  43. Makushkin EV, Badmaeva VD, Dozortseva EG, Syrokvashina KV, Oshevsky DS, Chibisova IA, Terekhina SA. Age characteristics of mental development and the state of minors who have committed suicides. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(7-2):20-24. (In Russ.). https://doi.org/10.17116/jnevro201911907220
  44. Osipova NN, Dmitrieva EV, Beglyankin NI, Bardenshtein LM. Predictors of suicidal behavior in adolescents with depressive disorders. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(1-2):28-33. (In Russ.). https://doi.org/10.17116/jnevro20191191228
  45. Van Meter A, Moreira ALR, Youngstrom E: Updated meta-analysis of epidemiologic studies of pediatric bipolar disorder. J Clin Psychiatry. 2019;80:18r12180. https://doi.org/10.4088/JCP.18r12180
  46. Lee EJ, Hower H, Jones RN, Birmaher B, Strober M, Goldstein BI, Merranko J, Keller MB, Goldstein TR, Weinstock LM, Dickstein DP, Hunt JI, Diler RS, Ryan ND, Gill MK, Axelson D, Yen S: Course of longitudinal psychosocial functioning in bipolar youth transitioning to adults. J Affect Disord. 2020;268:109-117.  https://doi.org/10.1016/j.jad.2020.03.016
  47. Post RM, Altshuler LL, Kupka R, McElroy SL, Frye MA, Rowe M, Grunze H, Suppes T, Keck PEJr, Nolen WA. Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood J Clin Psychiatry. 2010;71(7):864-872.  https://doi.org/10.4088/JCP.08m04994yel
  48. DelBello M, Goldman R, Phillips D, Deng L, Cucchiaro J, Loebel A. Efficacy and safety of Lurasidone in children and adolescents with bipolar depression: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2017;12:56(12):1015-1025. https://doi.org/10.1016/j.jaac.2017.10.006
  49. DelBello MP, Tocco M, Pikalov A, Deng L, Goldman R. Tolerability, Safety, and Effectiveness of Two Years of Treatment with Lurasidone in Children and Adolescents with Bipolar Depression. Journal of Child and Adolescent Psychopharmacology. 2021;31:7.  https://doi.org/10.1089/cap.2021.0040
  50. Singh MK, Pikalov A, Siu C, Tocco M, Loebel A. Lurasidone in children and adolescents with bipolar depression presenting with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology. 2020. 30:10.  https://doi.org/10.1089/cap.2020.0018
  51. Colizzi M, Bortoletto R, Zoccante L. The Effectiveness of Lurasidone Add-On for Residual Aggressive Behavior and Obsessive Symptoms in Antipsychotic-Treated Children and Adolescents with Tourette Syndrome: Preliminary Evidence from a Case Series. Children. 2021;8:121.  https://doi.org/10.3390/children8020121
  52. Lee ES, Vidal C, Findling RL. A Focused Review on the Treatment of Pediatric Patients with Atypical Antipsychotics. J Child Adolesc Psychopharmacol. 2018;28(9):582-605.  https://doi.org/10.1089/cap.2018.0037
  53. Millard H, McLaren JL, Discussant: Barbara J. Coffey Lurasidone Treatment in a Child with Autism Spectrum Disorder with Irritability and Aggression. Journal of Child and Adolescent Psychopharmacology. 2014;24(6):354-356. Advanced Pediatric Psychopharmacology. https://doi.org/10.1089/cap.2014.2462
  54. Lynn McClellan, Kelli C. Dominick, Ernest V. Pedapati, Logan K. Wink, Craig A. Erickson Lurasidone for the treatment of irritability and anger in autism spectrum disorders. Expert Opinion on Investigational Drugs. 2017;26(8):985-989.  https://doi.org/10.1080/13543784.2017.1353600
  55. Shafiq S, Pringsheim T. Using antipsychotics for behavioral problems in children. Expert Opin Pharmacother. 2018;19(13):1475-1488. https://doi.org/10.1080/14656566.2018.1509069
  56. Harvey P, Goldman R, Tocco M, Deng L. Effect of Lurasidone on cognition in adolescents with schizophrenia: interim analysis of a 2-year open-label extension study. Schizophrenia Bulletin. 2018;44(1):353.  https://doi.org/10.1093/schbul/sby018.860
  57. Zimmerman M, Pfohl B, Coryell WH, Corenthal C, Stangl D. Major depression and ersonality isorder. J Affect Disord. 1991;22(4):199-210.  https://doi.org/10.1016/0165-0327(91)90066-2
  58. Kobzova MP, Zvereva NV, Goryunov AV, Shchelokova OA, Simonov VN. Cognitive functions, features of social functioning and self-esteem in young men with schizotypal disorder who fell ill in adolescence. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2013;113(11):17-21. (In Russ.).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.